Tag: C1 inhibitor

Hereditary angioedema (HAE) is a rare genetic disorder affecting an estimated 1 in 50,000 people worldwide [1.4.2]. C1 inhibitor drugs are a primary treatment, working by replacing a crucial protein to prevent or treat severe swelling attacks [1.2.3, 1.2.1].

While corticosteroids and antihistamines are often ineffective for hereditary angioedema (HAE), specific targeted therapies are required. This guide explains **what medication is injected for angioedema**, detailing the treatments tailored for different underlying causes.

Over 200,000 Americans are estimated to have a rare disease known as Hereditary Angioedema (HAE), a condition caused by a deficiency or dysfunction of the C1 esterase inhibitor protein. The standard of care often involves replacing this missing protein, which is available under several different brand names for C1 inhibitor concentrate, including Berinert, Cinryze, and Haegarda.

Hereditary Angioedema (HAE) is a rare genetic condition causing episodes of severe swelling due to low or malfunctioning C1 esterase inhibitor (C1-INH). While both HAEGARDA and Berinert are C1-INH replacement therapies, a crucial distinction exists regarding their use: HAEGARDA is a routine prophylactic to prevent attacks, while Berinert is an on-demand treatment for acute attacks. Understanding their separate functions is vital for managing HAE effectively.